AJ Vaccines To Develop Vaccine for COVID-19
Danish vaccine manufacturer AJ Vaccines has initiated the development of a new vaccine, effective for protection against coronavirus COVID-19. The vaccine candidate will use technology to raise strong immune responses while being well tolerated and to meet potential global demand in 2021.
COPENHAGEN, Denmark -- (BUSINESS WIRE) --
“This endeavor reiterates our ambition to serve the global community, not only with existing effective high-quality vaccines, but also with the development of innovative new vaccines to answer the current global challenge of coronavirus COVID-19”, says Dr Tabassum Khan, Chairman to AJ Vaccines.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200306005124/en/
Committed to prevent serious disease globally
“The impact of the COVID-19 disease globally is developing by the hour and we are committed to a world free of serious diseases across all generations. Our employees are aware of the current challenges and are dedicated to finding solutions to the COVID-19 challenge with state-of-the-art technology”, says Jesper Helmuth Larsen, CEO AJ Vaccines.
High protection, low risk of side effects
“The main principle of vaccination is to proactively induce a protective immune response by mimicking the natural interaction of infectious pathogens with our immune system. Modern antigen technology allows for the production of vaccines combining high protection with a low reactogenicity and favorable safety profile as compared to some of the more traditional vaccines. Our aim is to combine the best possibly designed antigens in such a way to mimic closely the authentic native structures of the virus. Similar technologies were previously successfully applied in US FDA-approved vaccines. In short, the use of such technology is expected to induce the relevant immune responses and therefore protect against disease with a lower risk for side effects”, concludes Jerome Cabannes, COO AJ Vaccines.
Notes for editors
AJ Vaccines Group based in Copenhagen Denmark develop and manufacture vaccines against serious infectious diseases such as tetanus, diphtheria, tuberculosis, pertussis (whooping cough) and polio. In addition, the Group manufactures Tuberculin for screening and diagnosis of high-risk patients for infection with TB, and BCG Culture (Danish strain 1331) for the standard treatment for intermediate and high-risk non-muscle invasive bladder cancer. Our affiliate office in Malaysia focuses on in-licensing and developing, newer more effective vaccines and diagnostics relevant to the region, such as leptospirosis, influenza and cholera.
The company has some 750 employees and expects to expand its skilled workforce in order to fulfill the ambitious growth plans.
See more at: http://www.ajvaccines.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200306005124/en/
Carestream Health将其医疗保健IT业务
Vifor Pharma and Angion
DCAS开始接受2024年非经销商委员会会员申请
Aeternals:新型NFT和互动技术相结合
Rimini Street荣获多项客户销售与服务世界奖
聚豪情商务联盟携手天赐良田,玖夫牌富硒大米
Spesolimab meets primary
Boehringer Ingelheim Launches
IDEMIA和Resa Airport Data Syst
电池生产商Hithium将为储能系统开发商Perfect
Sabre选择DXC Technology来助力改变未
面对疫情和经济危机,亿康先达发布强劲的20
回顾激情燃烧的建设岁月 传承兰西拉艰苦奋斗
Mythical Games完成3700万美元C1轮融资
Kymeta 宣布其下一代天线、终端和全球移动连接
苏爱康医药宣布在日本推出Darvias®
在大地上书写责任与担当——渭南师范学院孙樵
森永乳业的益生菌长双歧杆菌BB536在其50周年庆
深圳三匹马出行科技与江铃集团新能源战略合作
Mavenir的虚拟无线接入网(vRAN)连续第二年在
村田首款面向Wi-Fi 6E/7的寄生元件耦合器实现商
广成明股份参加番禺区先进制造业强区座谈会
Intelsat向史密森国家航空航天博物馆捐赠
全球投资者法律顾问ROSEN鼓励Athira Pharma